Clinical Research Jinghua Weikang Capsules Plus PPI Triple Therapy Hp-related Chronic Gastritis

Background:Hp infection is a major cause of chronic gastritis, and therefore eradication of Hp is the most critical step in the treatment of HpAG current Western medicine is mainly used in quadruple therapy, PPI+bismuth+two antimicrobial agents. But with the increase of Hp resistance, antibacterial drug side effects highlights, making Hp eradication rate decreased gradually getting higher and higher relapse rates, which prompted many scholars began looking for new ways to eradicate, and the combination of traditional Chinese medicine has become almost Most years, Jing Weikang Pill that is developed in this context. Early experiments suggest that Jing Weikang Pill Hp in vitro inhibition and has a strong role in the killing, and with the western union, a common collaborative role; in early clinical observation, Jing Weikang Pill able to Hp-related clinical symptoms of abdominal pain, fullness caused by chronic gastritis, belching, heartburn and acid reflux, have significant improvement, so this is also the subject of the research, namely Jing Weikang Pill combined PPI triple therapy Hp-related provides the basis for chronic gastritis.Objective:The study observed Jing Weikang Pill PPI triple therapy combined effect of Hp-related chronic gastritis, including Hp eradication rate of clinical symptoms and improve two aspects of Integrative Medicine Hp-related chronic gastritis the new study provides the basis.Methods:In this study, the patients mainly from the Beijing University of Chinese Medicine Eastern Hepatobiliary Hospital outpatient stomach and digestive endoscopy centers, a total of104cases, taking randomized double-blind grouping method, were divided into treatment group and control group, the treatment group received Jing Weikang Pill joint PPI triple therapy (lansoprazole30mg bid+amoxicillin1000mg bid+clarithromycin500mg bid+Jing Weikang Pill160mg, tid, eradication therapy for10days, then take a separate Jing Weikang Pill2weeks); control group received quadruple therapy (lansoprazole30mg bid+amoxicillin1000mg bid+clarithromycin500mg bid+bismuth potassium citrate220mg bid, eradication therapy10days). General information were assessed before and after treatment, the clinical symptoms of comparability, recording changes in symptoms and adverse events during the medication, the symptoms improved after treatment were compared (including intra-group and group before and after comparison), and to compare the two group withdrawal effects after28days of Hp eradication.Results:(1) HP eradication rate in the treatment group was84.4%vs88.9%, the former than the latter, but the statistical analysis, P=0.535>0.05, there is no statistical difference between the two, the effect is quite;(2) in terms of the overall improvement in symptoms, compared with pre-treatment, two episodes in the extent and frequency of seizures, the average P<0.05, two general description of symptoms were significantly improved;(3) in terms of individual symptoms were conducted before the group, the two groups P<0.05, two groups described the symptoms to improve, both in the degree of attack or seizure frequency, are relatively obvious;(4) in the individual symptoms, the two inter-group group, anorexia symptoms P>0.05, indicating that both anorexia and no significant difference in terms of the improvement of individual symptoms, the effect is quite, but the other three individual symptoms, joint capsules Jing Wei Kang spent on PPI triple bloating (effective rate of93.6%) was significantly higher than83.7%of the control group quadruple; Jing Weikang Pill group belching effective rate of95.7%, higher than the87.8percent quadruple groups; the pain of the effective rate of97.9%, also higher than the95.9percent quadruple group.Conclusions:(1) In Hp eradication, Jing Weikang Pill combined PPI triple therapy group and control group, the effect of quadruple bismuth-containing considerable;(2) in terms of symptom improvement, Jing Weikang Pill PPI triple therapy group in the United bloating, belching, abdominal pain, improve aspects of the control group than quadruple bismuth-containing agent.